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Introduction:  the standard treatment for locally advanced extra-peritoneal rectal adenocar-
cinoma, consists of neoadjuvant treatment with radiotherapy and chemotherapy followed 
by total mesorectal excision.  
Objective: evaluate, retrospectively, the patients submitted to neoadjuvant therapy and surgery 
that presents with total remission of the lesion in the anatomopathological examination. 
Methods: between 2000 and 2010, 212 patients underwent surgery at the Coloproctology 
Unit at DMAD at FCM–UNICAMP. They were grouped as: rectosigmoidectomy and colorectal 
anastomosis (n = 54),  rectosigmoidectomy with coloanal anastomosis (n = 41), 114 abdomi-
noperineal resection of the rectum (n = 114) and  other (n = 3). 
Results: thirty (14.2%) patients (mean age 57.6 years; 60% males) showed complete remis-
sion of the rectal lesion. 4 (13.3%) had compromised lymph nodes and/or lymphatic inva-
sion
At follow-up (mean 51.9 months), 4 (13.3%) presented with local recurrence (one patient) or 
distant metastases (two patients had liver metastasis, one had liver and lung, and one had 
bone metastasis). The mean survival was 86.7%.  
Conclusion: patients with a complete tumor response show ed an increased survival rate, 
however, the same patients without evidence of residual tumors could develop local recur-
rence or distant metastases on a later follow-up.
Study carried out at the Service of Coloproctology of the Discipline of Digestive System Diseases (DMAD) of the Departament of Sur   
gery of the School of Medical Sciences (FCM) of Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
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r e s u m o
Terapia neoadjuvante e cirurgia no adenocarcinoma retal: análise dos 
pacientes com remissão tumoral completa no reto
Introdução: o tratamento padrão do adenocarcinoma de reto extra-peritoneal localmente 
avançado consiste de neoadjuvância com radio e quimioterapia, seguida de cirurgia com 
excisão total do mesorreto.  
Objetivo: avaliar, retrospectivamente, os pacientes submetidos à neoadjuvância e cirurgia, 
que apresentaram remissão completa da lesão no reto no exame anatomopatológico.
Métodos: foram avaliados 212 doentes, operados no Serviço de Coloproctologia da DMAD 
da FCM-Unicamp, entre 2000 e 2010. As cirurgias realizadas foram: retossigmoidectomia 
e anastomose colorretal (n = 54), retossigmoidectomia com anastomose coloanal (n = 41), 
amputação abdominoperineal do reto (n = 114) e outras (n = 3).  
Resultados: trinta (14,2%) pacientes (média de idade de 57,6 anos; 60% do sexo masculino) 
apresentaram remissão tumoral completa no reto; destes, 4 (13,3%) tinham acometimento 
linfonodal e/ou invasão linfática. No seguimento pós-operatório (médio de 51,9 meses), 4 
(13,3%) apresentaram recidiva local (um doente) ou metástases à distância (dois doentes 
com metástases hepáticas, uma hepática e pulmonar, e um outro metástase óssea). A so-
brevida média do grupo foi de 86,7%. 
Conclusão: os pacientes com resposta tumoral completa no reto apresentaram elevada taxa 
de sobrevida, mas mesmo doentes sem evidência de tumor residual, podem apresentar 
recidiva local ou metástases à distância no seguimento tardio.
Introduction
Colorectal cancer is the third most common malignant neo-
plasia worldwide and the third main cause of cancer mortal-
ity in the United States, with rectal carcinoma comprising 
approximately 30% of these cases.1 While the occurrence of 
colon cancer is similar between genders, rectal cancer is 20% 
to 50% more frequent in men, afflicting especially the age 
group between 50 and 70 years. The mean survival, in five 
years, is estimated at  40% to 50%.2 
Traditionally, the multimodal therapy is recommended 
in the treatment of rectal cancer, including radiotherapy as-
sociated with neoadjuvant chemotherapy and subsequent 
surgical approach with total mesorectal excision. The main 
objective is the improvement in survival and local control of 
the disease, in addition to maintenance of urinary and sex-
ual function, and preservation of the anal sphincter, thereby 
avoiding the definitive colostomy.3
The use of neoadjuvant therapy has proven to be effective 
in reducing tumor size, facilitating surgical resection and al-
lowing sphincter preservation. Some studies also show few-
er affected lymph nodes and absence of residual neoplas-
tic disease. In these cases, the neoadjuvant treatment was 
enough to lead to a complete pathological response, or lack 
of tumor cells in the surgical specimen.4
With the improvement of radiotherapy techniques and 
the development of new chemotherapeutic agents, there 
has been progressive improvement in the results of neoad-
juvant therapy with complete tumor response rates rang-
ing from 20% to 35%.5 The favorable results of preoperative 
therapy have raised questions about the need for a surgical 
approach. Thus, some authors have posited the validity of 
the non-surgical treatment in cases of complete response to 
neoadjuvant therapy.4,6-10
Patients and methods
A retrospective analysis of a consecutive series of 212 patients 
with a diagnosis of extra-peritoneal rectal adenocarcinoma, 
submitted to neoadjuvant therapy followed by surgical resec-
tion with curative intention. Procedures were carried out at 
the Coloproctology Service of the Discipline of Digestive Sys-
tem Diseases (DMAD) of Universidade Estadual de Campinas 
(Unicamp) between 2000 and 2010. 
The variables analyzed were: age, gender, ethnicity, 
tumor differentiation, TNM staging and type of surgery 
performed. Complete tumor regression was considered 
in the absence of viable neoplastic cells in the surgical 
specimen from the rectum. The neoadjuvant radiotherapy 
consisted of a dose of 4.500-5040 cGy and 5-fluorouracil 
(5-FU) for chemotherapy.
The following data was obtained from the group of pa-
tients with complete tumor response: time of symptom evo-
lution until surgery, distance between the tumor and the anal 
verge, preoperative colonoscopy, staging tests (chest radiog-
raphy/tomography computed, total abdominal ultrasound/to-
mografic computed, carcinoembryonic antigen [CEA] levels), 
time between neoadjuvant therapy and surgery, type of sur-
gery, intraoperative findings, and anatomopathological analy-
sis of the surgical specimen and follow-up, including survival 
and recurrence. 
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Results
From 212 patients, 124 (58.5%) were males, 179 (88.4%) were 
Caucasian and the mean age was 59.9 years, ranging from 29 
to 88 years. The surgeries performed were: 54 (25.5%) recto-
sigmoidectomies with colorectal anastomosis, 41 (19.3%) rec-
tosigmoidectomies with coloanal anastomosis, 114 (53.8%) 
abdominoperineal resection of the rectum and three (1.4%), 
other surgeries.
The anatomopathological study showed 30 (14.2%) pa-
tients with no residual tumor in the rectum (Fig. 1). Of the 
remaining 182 (85.8%), 5 (2.4%) were Tis tumors, 9 (4.2%) T1; 
62 (29.2%) T2; 81 (38.2%) T3 and 25 (11.8%) were T4. (Eighteen 
9.9%) were well-differentiated tumors, 152 (83.5%) moderately 
differentiated, and 12 (6.6%), poorly differentiated. 
In the study group (patients with complete remission, the 
surgeries performed were: rectosigmoidectomy with colorec-
tal anastomosis in 6 (20%), rectosigmoidectomy with coloanal 
anastomosis in 9 (30%) and abdominoperineal resection of 
the rectum in 15 (50%). When performing the intraoperative 
assessment, there were lesions suggestive of liver metastases 
in 3 (10%) and invasion of adjacent organs in other 2 patients 
(6.7%). The data of the 30 patients who had complete tumor 
response are shown in Table 1. 
Two patients underwent surgery for intestinal obstruction 
with defunctioning sigmoidostomy, before the completion of 
neoadjuvant therapy. At the colonoscopy, 6 (20.0%) patients 
had benign synchronous lesions and in 2 (6.7%) it was not 
possible to evaluate the proximal colon due to tumor stenosis. 
In the preoperative examinations, no patient had lung metas-
tases and 1 (3.3%) patient had liver metastasis. The level of 
CEA was higher than 5 μg / L in 10 (33.3%) patients.   
The interval between neoadjuvant therapy and surgery was 
less than four weeks in 8 (26.7%) patients, four to eight weeks 
in 12 (40%) and more than eight weeks in 7 (23.3%) patients; 
this information was undetermined for 3 (10%) patients. 
The anatomopathological analysis of the surgical speci-
men showed that 2 (6.7%) patients had lymphatic invasion, 
and 1 (3.4%) of them also had 5 affected lymph nodes. Other 2 
patients also had lymph node involvement, respectively, with 
1 and 10 affected lymph nodes. No patient had perineural in-
vasion. 
The mean postoperative follow-up was 51.9 months; 4 
(13.3%) patients showed distant metastases (two in the liver, 
one in the lung and liver and one had bone metastasis) and 
one of these also developed pelvic recurrence and was reop-
erated 59 months after the first intervention. Of the patients 
with liver metastases, one had synchronous liver metastasis 
in the preoperative period of the rectal surgery and the sec-
ond one had lymph node involvement and lymphatic inva-
sion revealed in the anatomopathological assessment.
Twenty-six (86.6%) patients remain alive. The mean sur-
vival of the group with complete remission was 86.7%, with 3 
(10%) patients lost at follow-up. The survival curve is shown 
in Fig. 2. 
Table 1 – General and specific data.
Data n = 30
Gender (M / F) 18 / 12 (60% / 40%)
Mean age (years) 57.6 (33 – 79)
Ethnicity (C / NC) 27 / 3 (90% / 10%)
Time of evolution (months) 16.1 (2 – 41)
Location of lesion
        < 5 cm from the AV 16 (53.3%)
        > 5 cm from the AV 14 (46.7%)
Metastases (pre-op.)
        liver 1 (3.33%)
        lung 0 (0%)
Colonoscopy (pre-op)
        synchronic lesions 6 (20%)
        stenosing tumor 2 (6.7%)
CEA (pre-op)
        < 5 μg/L 20 (66.7%)
        > 5 μg/L 10 (33.3%)
Interval between neoadjuvant 
therapy and surgery
        < 4 weeks 8 (26.7%)
        4 - 8 weeks 12 (40%)
        > 8 weeks 7 (23.3%)
        no information 3 (10%)
Intraoperative finding 
        Liver metastasis 3 (10%)
        Invasion of  adjacent organs  2 (6.7%)
AV, anal verge; CEA, carcinoembryonic antigen. 
Fig. 1 -  Sample of rectal amputation after neoadjuvant 
therapy with no residual malignancy.
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Discussion
The treatment of distal rectal cancer remains a challenge for 
surgeons worldwide. A multimodal approach has been pre-
ferred for the management of these patients. This includes 
neoadjuvant chemotherapy and radiotherapy combined with 
surgery with total mesorectal excision and adjuvant chemo-
therapy in cases of lymph node involvement or distant me-
tastases. 
Neoadjuvant treatment can result in downstaging, with 
reduction in tumor size, degree of rectal wall penetration and 
even lymph node sterilization. This response, in addition to 
allowing better surgical outcomes with anal sphincter pres-
ervation and reduction in permanent colostomies, is related 
to better rates in local recurrence and overall survival.3,11 In 
some cases, the complete regression is evident, defi ned as the 
absence of neoplastic cells, determined by anatomopatho-
logical analysis after rectal resection. This particular scenario 
is found in  5% to 30% of patients treated with neoadjuvant 
therapy and surgery.3,12,13 
In the present study, we found complete tumor response in 
30 patients, representing 14.2% of the sample. Despite being 
within the range reported in the literature, the value found 
is a little below the best results, possibly suggesting differ-
ences in the neoadjuvant treatment and in the time interval 
between neoadjuvant therapy and surgery. In this study, the 
time between neoadjuvant treatment and surgical resection 
was predominantly 4 to 8 weeks, the same verifi ed by Nyas-
avajjala et al., who observed tumor remission rates of 10%.15 
Recent literature has demonstrated that longer periods 
between neoadjuvant therapy and surgery may result in 
higher rates of complete response.3,14-16 Sloothaak et al., as-
sessing 1593 patients, found that the higher rate of complete 
remission of the tumor was observed when the surgery was 
delayed until the 15th or 16th week after the beginning of the 
neoadjuvant therapy, which corresponds to 10-11 weeks after 
its completion.18 
The results indicating the absence of tumor lesion in the 
surgical specimen have raised questions about the need for 
the surgical treatment, considering the current diagnostic 
methods. However, to date there is no test available capable 
to confi rm with certainty the tumor disappearance from the 
rectum and/or lymph nodes. 
Current diagnostic tests for evaluation include imaging 
methods such as endorectal ultrasound and magnetic nuclear 
resonance. As for the detection of lymph node involvement, 
endorectal ultrasonography has a sensitivity and specifi city 
of 55% and 78%, respectively. 19 Rectal examination by colo-
noscopy or digital rectal examination (DRE) are not suffi cient 
to guarantee the absence of neoplasia, as well as the magnetic 
resonance to demonstrate the disappearance of tumor cells 
both in the primary tumor and lymph nodes. Furthermore, 
the distinction between residual tumor, intramural fi brosis or 
actinic ulcers can be diffi cult.3,17  
Perez et al., evaluating the effectiveness of Positron Emis-
sion Tomography (PET)/CT, assessed 99 patients with rectal 
cancer after 12 weeks of neoadjuvant treatment using the 
imaging method and obtained 5 false negative and 10 false 
positive results. Aiming to detect residual tumor, the sensitiv-
ity was 93% and the specifi city was 53%. Clinical evaluation 
resulted in  accuracy of 91% and the information disclosed by 
the PET-CT improved the accuracy up to 96%.20 
Studies have shown that patients with apparent total 
remission submitted to neoadjuvant therapy and local re-
section (mostly because of comorbidities or patient refusal) 
have an overall satisfactory and disease-free survival, with 
no difference compared to those who underwent radical sur-
gery.21,22 
Pelvic recurrence is a major concern in the treatment of 
rectal cancer and could be associated with the level of tumor 
penetration in the bowel wall, presence of affected lymph 
nodes, resection margins and surgical techniques. The target 
of a large number of studies, local recurrence rate has shown 
to be extremely variable, from 3% to 30%.3 In the present 
study, only one (3.4%) patient had local recurrence, but this 
sample involves only patients who had complete remission 
of rectal lesions. Habr-Gama et al., following 67 patients with 
complete remission and non-operated, found recurrence in 
15 (21%) patients, with 8 rectal,  and 7 distant metastases and 
no pelvic recurrence. 8
Campos-Lobatto et al. assesed 58 patients with complete 
remission, found no local recurrence and this group also had 
fewer distant metastases. Overall survival was also statistically 
signifi cantly better than in the group with residual disease.23
Three meta-analyses, with a signifi cant number of pa-
tients, showed that patients with complete tumor remission 
after neoadjuvant therapy had high survival rates and low re-
currence of cancer.24-26 Of the 3,105 patients in the study, Maas 
et al. found that 484 had complete remission, ranging be-
tween 8% and 24% in the different studies. They observed 61 
recurrences and this group had a 5-year survival rate of 83.3%, 
compared with 65.6% among those with residual tumor.24 Of 
the 3,363 patients (1263 with complete remission and 2100 
with residual tumor) of the study, Martin et al. observed 0.7% 
of local recurrence, 8.7% of distant metastases, 90.2% of over-
all survival and disease-free survival of 87% in patients with 
complete remission, with the difference being statistically 
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Fig. 2 – Survival curve.
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significant when compared to the group that showed residual 
tumor after the neoadjuvant therapy.25
Zorcolo et al. observed complete tumor response in 300 
(15.6%) patients. They found that patients with complete re-
mission after neoadjuvant therapy had better local and dis-
tance control, as well as better overall and disease-free sur-
vival.26 
Smith et al. found that most patients with complete patho-
logical response did not have complete clinical improvement. 
T1/T2 tumors showed small mucosal abnormalities and had 
low risk of lymph node involvement, potentially facilitating 
local resection. The risk of lymph node metastasis was as-
sociated significantly with poorer tumor differentiation and 
presence of lymphovascular invasion.27 Tranchart et al. also 
found in their sample that patients with T3 tumors had more 
affected lymph nodes than patients with T1-T2 tumors, 46% 
and 7% respectively.28   The rate of lymph node involvement 
in patients with complete tumor response ranged from 0% to 
10%,29,30 whereas in our study, 13.3% of patients had lymph 
node metastases and one of them developed pelvic lymph 
node recurrence. 
Habr-Gama and collaborators have carried out studies to 
find evidence for not performing surgery in these patients. 
It has been documented that a proportion of these patients 
might develop metastases during treatment after neoadjuvant 
therapy or even after complete tumor response, representing 
the presence of non-detectable tumor cells.3,17 Therefore, even 
patients with complete tumor remission need follow-up with 
periodic clinical and imaging method assessment, which to-
gether will provide confidence to the professional. 
In conclusion, the neoadjuvant therapy resulted in a sig-
nificant number of patients with no residual primary tumor. 
Although the percentage of patients with complete tumor re-
gression was a little lower than some values reported in the 
literature, this group had a high survival rate. However, in the 
late follow-up, even patients with complete remission of rec-
tal cancer with neoadjuvant therapy may show distant dis-
ease recurrence or even local recurrence. 
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